Cambridge, United States
Orbital Therapeutics, founded in 2022 and headquartered in the United States, stands at the forefront of innovation in the burgeoning field of RNA medicines. The company's mission is succinctly encapsulated in its slogan: "Expanding RNA medicines to more tissues, more diseases, and more patients."
The startup is pioneering a new generation of RNA therapies aimed at reprogramming cells in vivo, thus offering patients a promising alternative to complex treatments. At the core of Orbital’s strategy is a fully integrated platform that combines circular and linear RNA, targeted delivery systems, and AI-guided design methodologies. This empowers the company to create durable and programmable therapies specifically tailored to combat the distinct biology of various diseases.
Orbital's lead program, OTX-201, focuses on autoimmune diseases and aims to restore immune balance via B cell depletion. The company's platform's versatility allows potential expansion into oncology, vaccines, and protein therapeutics. In a strategic move, Orbital secured a significant investment of $1.50 billion from Bristol-Meyers Squibb in October 2025, signaling a strong vote of confidence in their pioneering approach and potential for growth.
